| Health / Medical Topics |
Pacritinib
An orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V617F with potential antineoplastic activity. Oral JAK2 inhibitor SB1518 competes with JAK2 for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, and so caspase-dependent apoptosis. JAK2 is the most common mutated gene in bcr-abl-negative myeloproliferative disorders; the JAK2V617F gain-of-function mutation involves a valine-to-phenylalanine modification at position 617. The JAK-STAT signaling pathway is a major mediator of cytokine activity. (NCI Thesaurus)
YOU MAY ALSO LIKE
A form of the anticancer drug paclitaxel used to treat breast cancer, ovarian cancer, and AIDS-related Kaposi sarcoma. It is also used…
A cremophor-free, P-glycoprotein-inhibiting, vitamin E-based emulsion particle formulation of paclitaxel with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of…
Any formulation containing paclitaxel, an antimitotic taxane.
A paclitaxel formulation containing paclitaxel incorporated in biodegradable polyphosphoester (PPE) polymer form with potential antineoplastic activity. Upon intraperitoneal delivery, paclitaxel PPE microspheres…
A form of the anticancer drug paclitaxel combined with a protein called poliglumex that may have fewer side effects and work better…
A form of the anticancer drug paclitaxel combined with a protein called poliglumex that may have fewer side effects and work better…
